Popular Articles

Pharmacy Bodies Call For Reinstatement Of Community Pharmacists To The Shortage Occupations List, UK
The CCA, AIMp, BPSA, and NPA are appealing for an immediate reinstatement of community pharmacists to the Shortage Occupations List after the removal of community pharmacists from the list by the Migration Advisory Committee (MAC) last month.
generic viagra online
Lupus Research Institute Highly Encouraged By Benlysta(TM) Trial Results
The Lupus Research Institute (LRI) and its National Coalition of state and local organizations congratulate Human Genome Sciences (HGS) and GlaxoSmithKline on the highly promising results of this landmark clinical trial of Benlysta(TM) (belimumab) for people with systemic lupus.
News of the day
Molecular Insight Pharmaceuticals, Inc. Receives European Medicines Agency Approval To Proceed With Phase 3 Development Of OnaltaTM
Molecular Insight Pharmaceuticals, Inc. (NASDAQ: MIPI) announced that the European Medicines Agency (EMEA) has approved its Phase 3 protocol for Onalta (Yttrium-90 edotreotide). Onalta is the Company"s lead radiotherapeutic product candidate under development for the treatment of metastatic carcinoid and pancreatic neuroendocrine tumors in patients whose symptoms are not controlled by conventional therapy. The compound has shown the potential to selectively deliver lethal radiation to cancer cells. The proposed Phase 3 trial will confirm that administration of Onalta results in stabilization, regression or complete remission of the carcinoid tumor, and improves carcinoid-related symptoms when compared to a high-dose regimen of the current standard therapy for this disease, Sandostatin®. With EMEA"s approval of its proposed Phase 3 protocol in hand, Molecular Insight can proceed with the final clinical trial that will position Onalta for marketing authorization in the EU.
Public Health

New Guidelines To Help Diagnose Bleeding Disorders

Nearly one percent of the population suffers from bleeding disorders, yet many women don"t know they have one because doctors aren"t looking for the condition, according to researchers at Duke University Medical Center. That"s about to change, now that an international expert consortium specifically outlined the definitive signs that may signal the presence of a bleeding disorder in women. The consortium"s recommendations are published online and will appear in the July issue of the American Journal of Obstetrics and Gynecology. The new guidelines aren"t just for doctors. Women who suffer from heavy menstrual cycles should be on the lookout for these signs as well, says Andra James, MD, a Duke obstetrician, who says about 25 percent of women with heavy menstruation may have an undiagnosed bleeding disorder. "Heavy bleeding should not be ignored," says James, the paper"s lead author. "When a woman"s blood can"t clot normally the most obvious sign is a heavy period." Yet when faced with these scenarios, most doctors aren"t suspecting a blood clotting problem is to blame. "Sometimes they think hormones are the cause, or fibroids," says James. "In some cases they recommend removal of the uterus or offer another gynecologic explanation when the real contributing factor is a blood clotting disorder." In previous studies, women who ultimately were treated for a bleeding disorder reported waiting 16 years, on average, before being diagnosed. In extreme cases, James says undiagnosed bleeding disorders have led to women bleeding to death during menstruation, childbirth and surgical procedures. The most common inherited bleeding disorder is von Willebrand disease, says James, author of 100 Questions and Answers About von Willebrand Disease (Jones and Bartlett). Common criteria for diagnosis include the presence of a family history of bleeding, personal history of bleeding and laboratory tests that indicate the lack of a protein called von Willebrand factor which is essential for clotting. Without the laboratory test, the consortium says women and doctors should be on the lookout for the following: * Heavy blood loss during menstruation * Family history of bleeding disorder * Notable bruising without injury * Minor wound bleeding that lasts more than five minutes * Prolonged or excessive bleeding following dental extraction * Unexpected surgical bleeding * Hemorrhaging that requires blood transfusion * Postpartum hemorrhaging, especially if occurs more than 24 hours after delivery. "Too often women think heavy bleeding is okay because the women in their family -- who may also have an undiagnosed bleeding disorder -- have heavy periods as well," says James. "We want women who continually experience abnormal reproductive tract bleeding, specifically heavy menstrual bleeding, to be alert to these other signs and approach their physicians about being evaluated." In addition, she says doctors should be asking the right questions and ordering appropriate laboratory tests in suspected patients. "Not every patient who has abnormal reproductive tract bleeding has a bleeding disorder, and most don"t," James says. "But since up to one-quarter do, this needs to be recognized. Once treated, these women can expect to have normal periods and go through childbirth safely." The consortium"s meeting received financial support from CSL Behring. Debbe Geiger Duke University Medical Center


Add your comment:
Name:
Site address: http://
Your message:
Enter today\\\\'s date, 2 digits
(spam protection):